Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
N ChartierJ EpsteinM SoudantC DahanM MichaudS Pittion-VouyovitchF GuilleminM DebouverieGuillaume MatheyPublished in: European journal of neurology (2018)
Patients with the most active forms of MS are the most likely to benefit from MITOX in the long term.